Cantor Fitzgerald Analysts Boost Earnings Estimates for CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Cantor Fitzgerald boosted their FY2026 earnings per share estimates for CRISPR Therapeutics in a research report issued on Tuesday, November 11th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($6.22) per share for the year, up from their prior estimate of ($6.71). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

Several other research analysts also recently commented on CRSP. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, September 23rd. Zacks Research upgraded CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Robert W. Baird lowered their price target on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Wells Fargo & Company set a $75.00 price target on CRISPR Therapeutics in a report on Monday, October 13th. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $67.84.

CRISPR Therapeutics Stock Performance

CRSP stock traded down $1.60 during mid-day trading on Thursday, reaching $50.59. 745,808 shares of the stock traded hands, compared to its average volume of 2,550,948. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $78.48. The business has a 50-day moving average price of $63.02 and a two-hundred day moving average price of $53.44. The stock has a market capitalization of $4.82 billion, a PE ratio of -9.09 and a beta of 1.89.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.15. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 56,213 shares of company stock worth $3,810,458. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. SVB Wealth LLC acquired a new stake in CRISPR Therapeutics during the first quarter valued at $25,000. Costello Asset Management INC acquired a new position in CRISPR Therapeutics in the 1st quarter valued at approximately $27,000. Atlantic Union Bankshares Corp bought a new position in shares of CRISPR Therapeutics during the 2nd quarter worth about $33,000. Thompson Investment Management Inc. acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $33,000. Finally, Optiver Holding B.V. boosted its position in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after buying an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.